Effective treatment of experimental glioblastoma by HSV vector-mediated TNFα and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration

Molecular Therapy

Volumn 2, Issue 2, 2000, Pages 114-120

  Niranjan, Ajay ^a   Moriuchi, Shusuke ^a   Lunsford, L Dade ^a   Kondziolka, Douglas ^a   Flickinger, John C ^a   Fellows, Wendy ^a   Rajendiran, Swaminathan ^a   Tamura, Masakazu ^a   Cohen, Justus B ^a   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; HERPES; MUS MUSCULUS;

ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; CERCOPITHECUS; DEFECTIVE VIRUS; ENZYMOLOGY; FEMALE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMEDIATE EARLY GENE; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; RADIOSURGERY; SURVIVAL; TIME; VERO CELL;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; DEFECTIVE VIRUSES; FEMALE; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, IMMEDIATE-EARLY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOSURGERY; SIMPLEXVIRUS; SURVIVAL ANALYSIS; THYMIDINE KINASE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VERO CELLS;

EID: 0034242458     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0101     Document Type: Article

References (38)

1. Walker, M. D., Strike, T. A., and Sheline, G. E. (1979). An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 5: 1725-1731.
2. Alxander, E., III, and Loffler, J. S. (1998). Radiosurgery for primary malignant brain tumors. Semin. Surg. Oncol. 14: 43-52.
3. Gannett, D., Baldassarre, S., Lulu, B., Adair, T., Verdi, C., and Hamilton, A. (1995). Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 33: 461-468.
4. Hall, W. A., et al. (1995). Stereotactic radiosurgery for recurrent malignant gliomas. J. Clin. Oncol. 13: 1642-1648.
5. Kondziolka, D., Flickinger, J. C., Bissonette, D. J., Bosik, M., and Lunsford, L. D. (1997). Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41: 776-785.
6. Kondziolka, D., et al. (1996). Radiosurgery and fractionated radiation therapy: Comparison of different techniques in an in vivo rat glioma model. J. Neurosurg. 84: 1033-1038.
7. Loeffler, J. S., et al. (1992). Radiosurgery as part of the initial management of patients with malignant gliomas. J. Clin. Oncol. 10: 1379-1385.
8. Sarkaria, J. N., et al. (1995). Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys. 32: 931-944.
9. Packer, R. J., et al. (2000). Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. 92: 249-254.
10. Palu, G., et al. (1999). Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans. Gene Ther. 6: 330-337.
11. Trask, T. W., et al. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumors. Mol. Ther. 1: 195-203.
12. Barba, D., Hardin, J., Ray, J., and Gage, F. H. (1993). Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79: 729-735.
13. Culver, K., Ram, Z., Walbridge, S., Ishii, H., Oldfield, E., and Blaese, R. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.
14. Ezzeddine, Z. D., et al. (1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3: 608-614.
15. Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M., and Oldfield, E. H. (1986). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 46: 5276-5281.
16. Beltinger, C., Fulda, S., Kammertones, T., Meyer, E., Uckert, W., and Debatin, K. M. (1999). Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA 96: 8699-8704.
17. Freeman, S. M., et al. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53: 5274-5283.
18. Wu, J. K., Cano, W. G., Meylaerts, S. A., Qi, P., Vrionis, F., and Cherington, V. (1994). Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35: 1094-1102.
19. Marconi, P., et al. (2000). Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol. Ther. 1: 71-81.
20. Moriuchi, S., et al. (1998). Enhanced tumor-cell killing in the presence of ganciclovir by HSV-1 vector-directed co-expression of human TNF-α and HSV thymidine kinase. Cancer Res. 58: 5731-5737.
21. Staba, M.-J., Mauceri, H. J., Kufe, D. W., Hallahan, D. E., and Weichselbaum, R. R. (1998). Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 5: 293-300.
22. Krisky, D. M., et al. (1998). Development of herpes simplex virus replication defective multigene vectors for combination gene therapy applications. Gene Ther. 5: 1517-1530.
23. Krisky, D. M., et al. (1998). Deletion of multiple immediate early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5: 1593-1603.
24. Samaniego, L., Wu, N., and DeLuca, N. A. (1997). The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 71: 4614-4625.
25. Samaniego, L. A., Neiderhiser, L., and DeLuca, N. A. (1998). Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72: 3307-3320.
26. Wu, N., Watkins, S. C., Schaffer, P. A., and DeLuca, N. A. (1996). Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol. 70: 6358-6368.
27. Salcman, M. (1980). Survival in glioblastoma: Historical perspective. Neurosurgery 7: 435-439.
28. Walker, M. D., et al. (1978). Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49: 333-343.
29. Walker, M. D., et al. (1980). Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Engl. J. Med. 303: 1323-1329.
30. Cao, G., et al. (1997). Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor α gene transfer. Gastroenterology 11: 270-278.
31. Han, S. K., Brody, S. L., and Crystal, R. G. (1994). Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA. Am. J. Respir. Cell. Mol. Biol. 11: 270-278.
32. Ostensen, M. E., Thiele, D. L., and Lipsky, P. E. (1987). Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or inter-leukin-1 and interferon-alpha or interleukin-2. J. Biol. Res. Mod. 8: 53-61.
33. Owen-Schaub, L. B., Gutterman, J. U., and Grimm, E. A. (1988). Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 48: 788-792.
34. Pfizenmaier, K., Scheurich, P., Schluter, C., and Kronke, M. (1987). Tumor necrosis factor enhances HLA-A, B, C and HLA-DR gene expression in human tumor cells. J. Immunol. 138: 975-980.
35. Plaetinck, G., Declercq, W., Tavernier, J., Jabholz, M., and Fiers, W. (1987). Recombinant tumor necrosis factor can induce interleukin 2 receptor expression and cytolytic activity in a rat × mouse T cell hybrid. Eur. J. Immunol. 17: 1835-1838.
36. Ranges, G. E., Figari, I. S., Espevik, T., and Palladino, M. A., Jr. (1987). Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J. Exp. Med. 166: 991-998.
37. Gridley, D. S., Archambeau, J. O., Andres, M. A., Mao, X. W., Wright, K., and Slater, J. M. (1997). Tumor necrosis factor-α enhances antitumor effect of radiation against glioma xenograft. Oncol. Res. 9: 217-227.
38. Moriuchi, S., Krisky, D. M., Marconi, P. C., Tamura, M., Shimizu, K., Yoshimine, T., Cohen, J. B., and Glorioso, J. C. (2000). HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther., in press.